Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zymeworks Inc. - Common Stock (NQ:ZYME)

24.28 -0.85 (-3.38%)
Streaming Delayed Price Updated: 2:02 PM EDT, Jun 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Zymeworks Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Zymeworks Q1 Earnings Call Highlights ↗
Zymeworks (NASDAQ:ZYME) reported a wider first-quarter loss as revenue declined from year-earlier milestone payments, while management highlighted regulatory catalysts for zanidatamab, progress across... 
Via MarketBeat
Topics Earnings
Zymeworks (NASDAQ:ZYME) Misses Q1 Estimates But August PDUFA Date for Zanidatamab Offers Key Regulatory Catalyst ↗
Via Chartmill
News headline image
Zymeworks (ZYME) Q1 2026 Earnings Transcript ↗
Zymeworks (ZYME) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Capricorn Fund Makes a Huge Bet on Nerve Repair With 687,000 Share Axogen (AXGN) Investment Worth $22.4 Million ↗
This healthcare firm develops nerve repair solutions for hospitals and specialists in the U.S. and select global markets. 
Via The Motley Fool
Topics Regulatory Compliance
Zymeworks Inc (NASDAQ:ZYME) Posts Wider Q4 Loss Despite Strategic Progress and Royalty Deal ↗
Via Chartmill
ZYMEWORKS INC (NASDAQ:ZYME) Fits the Minervini Trend Template with High Growth Momentum ↗
Via Chartmill
News headline image
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗
Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships. 
Via The Motley Fool
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-market trading after reporting fourth-quarter results. Other stocks declining in pre-market trading... 
Via Benzinga
Topics Stocks
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
5 Analysts Have This To Say About Zymeworks ↗
 
Via Benzinga
News headline image
Zymeworks (ZYME) Q4 2025 Earnings Call Transcript ↗
Zymeworks (ZYME) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗
This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Which stocks are moving after the closing bell on Tuesday? ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
Zymeworks Stock Sees Surge In Retail Chatter After Royalty Pivot, Cancer Trial Win Sparks Target Price Hikes ↗
Strong new Phase 3 Ziihera data boosted confidence in upcoming regulatory milestones. 
Via Stocktwits
News headline image
Alphabet To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans ↗
Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings and guideline submissions. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
The market is filled with gapping stocks in Monday's session. ↗
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Mixed Signals Point to Cautious Open for U.S. Markets as Tech Shines Amidst Economic Data Delays
U.S. equity futures are signaling a mixed but largely cautious start to the trading day on November 17, 2025, with technology stocks once again taking the lead, while broader indices like the Dow Jones... 
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
News headline image
Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer ↗
Shares of Jazz Pharmaceuticals and Zymeworks catapulted Monday on positive test results for a gastric cancer drug. 
Via Investor's Business Daily
News headline image
These stocks are moving in today's pre-market session ↗
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Zymeworks Inc (NASDAQ:ZYME) Shows Strong Technical and Fundamental Momentum ↗
Discover how Zymeworks (ZYME) combines strong technical trends with accelerating earnings and sales growth, making it a top high-growth stock candidate. 
Via Chartmill
News headline image
Zymeworks Inc (NASDAQ:ZYME) Reports Mixed Q3 2025 Results with Narrower Loss but Revenue Miss ↗
Zymeworks Q3 2025: Narrower-than-expected loss and strong cash position, though revenue missed estimates. Clinical pipeline advances with promising data. 
Via Chartmill
News headline image
Broadcom To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
This RPM International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit ↗
Zymeworks discontinues ZW171 development after Phase 1 findings, refocusing on other cancer therapies in its pipeline, including ZW191 and ZW251. 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.